Retrospective Study
Copyright ©The Author(s) 2021.
World J Hepatol. Oct 27, 2021; 13(10): 1428-1438
Published online Oct 27, 2021. doi: 10.4254/wjh.v13.i10.1428
Table 3 Data regarding the patients evaluated for the HSD17B13:TA variant

All
HSD17B13 genotype
T/T
TA/T
TA/TA
n (%)3319 (57.58)12 (36.36)2 (6.06)
Females, n (%)161150
Mean age (yr)11.67 ± 3.1211.09 ± 3.4512.14 ± 2.2514.70 ± 3.24
Clinical presentation, n (%)
ALF and/or hemolytic anemia7 (21.21)5 (71.43)2 (28.57)0
Less severe hepatic forms26 (78.79)14 (53.85)10 (38.46)2 (7.69)
ATP7B variant
p.His1069Gln (c.3206A>G)/p.His1069Gln (c.3206A>G)5230
p.His1069Gln (c.3206A>G)/p.Gly1341Asp (c.4021G>A)6330
p.His1069Gln (c.3206A>G)/other7430
p.Gly1341Asp (c.4021G>A)/p.Gly1341Asp (c.4021G>A)7322
p.Trp939Cys (c.2817G>T)/p.Trp939Cys (c.2817G>T)4400
p.Trp939Cys (c.2817G>T)/other1100
p.Lys844Ter (c.2530A>T)/p.Lys844Ter (c.2530A>T)1100
p.Lys844Ter (c.2530A>T)/ other2110